Adding to your well-stated list of questions, melsdollars, it was deemed to be an ineffective way to determine viral inhibition with maravoric according to this study. Why are we being asked to demonstrate leronlimab dosing efficacy with RO?

https://pubmed.ncbi.nlm.nih.gov/18333870/

Quote:

---

Considering the imprecision of the measurement in the upper flat part of the maraviroc concentration vs. percent CCR5 occupancy curve, it can reasonably be concluded that routine monitoring of receptor occupancy as a biomarker for maraviroc efficacy will not be helpful. Based on this analysis, it was decided not to use receptor occupancy as a biomarker of viral load inhibition during the development of CCR5 antagonist compounds

---